FDA accepts Bausch Health, Clearside Biomedical's resubmitted Xipere NDA

Article

PDUFA action date of October 30, 2021, is assigned for investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.

FDA accepts Bausch Health, Clearside Biomedical's resubmitted Xipere NDA

Bausch + Lomb and Clearside Biomedical Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application for triamcinolone acetonide suprachoroidal injectable suspension (Xipere).

The agency determined that the filing is a Class 2 resubmission and assigned a Prescription Drug User Fee Act (PDUFA) action date of October 30, 2021, for the investigational therapy with a proposed indication of treatment of macular oedema associated with uveitis.

“If approved by the FDA, [triamcinolone acetonide suprachoroidal injectable suspension] would be the first therapy available utilising the suprachoroidal space for patients suffering from macular edema associated with uveitis, which is the leading cause of vision loss in people with uveitis,” said Yolande Barnard, vice president and general manager, US Pharmaceuticals, Bausch + Lomb, in a prepared statement.

“If approved, [this] would be our first commercial product and the first approved drug to be delivered into the suprachoroidal space (SCS),” added Clearside’s President and CEO George Lasezkay, PharmD, JD.

The novel treatment option is designed for suprachoroidal administration via Clearside’s proprietary SCS microinjector that provides access to the back of the eye, where sight-threatening disease often occurs.

An affiliate of Bausch Health acquired the exclusive license for the commercialisation and development of triamcinolone acetonide suprachoroidal injectable suspension in the United States and Canada in October 2019.

The Bausch Health affiliate also has exclusive options for the right to commercialise and develop the novel treatment option in the European Union, the United Kingdom, Australia and New Zealand, and/or South America and Mexico. Arctic Vision has the exclusive license for its commercialisation and development of in Greater China and South Korea. Triamcinolone acetonide suprachoroidal injectable suspension is not yet approved in any jurisdiction.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
© 2025 MJH Life Sciences

All rights reserved.